A double blind randomised study comparing the pharmacodynamic effects of Arimidex[anastrozole] with tamoxifen as neoadjuvant treatment of primary postmenopausal breast cancer

Next Previous
Trial Profile

A double blind randomised study comparing the pharmacodynamic effects of Arimidex[anastrozole] with tamoxifen as neoadjuvant treatment of primary postmenopausal breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2005

At a glance

  • Drugs Anastrozole (Primary) ; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms IMPACT

    • Most Recent Events

    • 01 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top